Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Progyny, Inc. $PGNY

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Progyny, Inc. (NASDAQ:PGNY) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 183,166 shares of the company’s stock, valued at approximately $3,110,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Progyny during the 4th quarter worth $25,000. Hantz Financial Services Inc. increased its holdings in shares of Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Progyny in the 2nd quarter valued at about $77,000. Quarry LP lifted its stake in shares of Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares during the period. Finally, New Age Alpha Advisors LLC acquired a new stake in shares of Progyny in the fourth quarter valued at about $94,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Up 0.4%

Progyny stock opened at $31.49 on Friday. The firm has a market capitalization of $2.47 billion, a PE ratio of 40.90, a P/E/G ratio of 2.49 and a beta of 1.01. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06. The firm’s 50-day simple moving average is $28.43 and its 200 day simple moving average is $23.20.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.24. The firm had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.46 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same period last year, the firm posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, research analysts expect that Progyny, Inc. will post 1.19 EPS for the current fiscal year.

Progyny announced that its Board of Directors has initiated a stock buyback plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Barclays restated an “equal weight” rating and set a $34.00 target price (up from $27.00) on shares of Progyny in a research report on Tuesday. Wall Street Zen downgraded shares of Progyny from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. BTIG Research boosted their price target on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Citizens Jmp upped their price target on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. Finally, Canaccord Genuity Group raised their price objective on Progyny from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Progyny has an average rating of “Moderate Buy” and an average target price of $33.25.

Insiders Place Their Bets

In other news, insider Geoffrey Clapp sold 1,530 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the transaction, the insider directly owned 59,117 shares of the company’s stock, valued at $1,512,212.86. This trade represents a 2.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kevin K. Gordon sold 5,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the completion of the sale, the director directly owned 9,318 shares in the company, valued at approximately $232,856.82. The trade was a 37.12% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 36,916 shares of company stock valued at $939,875. Corporate insiders own 9.90% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.